JP2022506898A5 - - Google Patents
Info
- Publication number
- JP2022506898A5 JP2022506898A5 JP2021525010A JP2021525010A JP2022506898A5 JP 2022506898 A5 JP2022506898 A5 JP 2022506898A5 JP 2021525010 A JP2021525010 A JP 2021525010A JP 2021525010 A JP2021525010 A JP 2021525010A JP 2022506898 A5 JP2022506898 A5 JP 2022506898A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- aryl
- ring
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760279P | 2018-11-13 | 2018-11-13 | |
| US201862760244P | 2018-11-13 | 2018-11-13 | |
| US201862760248P | 2018-11-13 | 2018-11-13 | |
| US62/760,279 | 2018-11-13 | ||
| US62/760,248 | 2018-11-13 | ||
| US62/760,244 | 2018-11-13 | ||
| US201962795373P | 2019-01-22 | 2019-01-22 | |
| US62/795,373 | 2019-01-22 | ||
| US201962796361P | 2019-01-24 | 2019-01-24 | |
| US201962796356P | 2019-01-24 | 2019-01-24 | |
| US62/796,356 | 2019-01-24 | ||
| US62/796,361 | 2019-01-24 | ||
| PCT/US2019/060775 WO2020102100A1 (en) | 2018-11-13 | 2019-11-11 | Compounds and compositions for treating conditions associated with nlrp activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506898A JP2022506898A (ja) | 2022-01-17 |
| JP2022506898A5 true JP2022506898A5 (cg-RX-API-DMAC7.html) | 2022-11-21 |
Family
ID=68916531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525010A Pending JP2022506898A (ja) | 2018-11-13 | 2019-11-11 | Nlrp活性に関連する状態を処置するための化合物及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12134611B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3880666B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022506898A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166081A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2957692T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020102100A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3649112A1 (en) * | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| CN114008030A (zh) * | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN117185965B (zh) * | 2023-09-18 | 2024-10-11 | 安徽金桐精细化学有限公司 | 一种磺酸基丙烯酸盐复配表面活性剂的制备方法 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
| WO2026064385A1 (en) * | 2024-09-18 | 2026-03-26 | Ventus Therapeutics U.S., Inc. | Oxadiazolone inhibitors of nlrp3 and uses thereof |
| CN119775202A (zh) * | 2024-12-31 | 2025-04-08 | 河南旭瑞新材料科技有限公司 | 一种2-巯基烟酰甘氨酸的合成方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
| CA2085297A1 (en) | 1991-12-20 | 1993-06-21 | James Edward Ray | Sulfonimidamides |
| US5705398A (en) | 1994-03-02 | 1998-01-06 | The Scripps Research Institute | Methods for identifying inhibitors of LPS-mediated LBP binding |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| PL344004A1 (en) | 1998-05-05 | 2001-09-10 | Hoffmann La Roche | Pyrazole derivatives as p-38 map kinase inhibitors |
| CN1832928B (zh) | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
| US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| US8884006B2 (en) | 2011-09-19 | 2014-11-11 | University Of Puerto Rico | Small-molecule inhibitors of Rac1 in metastatic breast cancer |
| ITMI20131658A1 (it) | 2013-10-08 | 2015-04-09 | Getters Spa | Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| US11447460B2 (en) * | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| MA44729A (fr) | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| EP3445761A1 (en) | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| KR102521955B1 (ko) | 2016-06-14 | 2023-04-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온 |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| US11370763B2 (en) | 2017-07-24 | 2022-06-28 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| PY1975819A (es) | 2018-09-13 | 2020-04-09 | Bayer Ag | Derivados heterocíclicos como plaguicidas.- |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| CN114008030A (zh) * | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
-
2019
- 2019-11-11 CN CN201980078239.1A patent/CN113166081A/zh active Pending
- 2019-11-11 JP JP2021525010A patent/JP2022506898A/ja active Pending
- 2019-11-11 EP EP19821320.9A patent/EP3880666B1/en active Active
- 2019-11-11 US US17/292,887 patent/US12134611B2/en active Active
- 2019-11-11 ES ES19821320T patent/ES2957692T3/es active Active
- 2019-11-11 WO PCT/US2019/060775 patent/WO2020102100A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505525A5 (cg-RX-API-DMAC7.html) | ||
| JP2022507065A5 (cg-RX-API-DMAC7.html) | ||
| JP2020528889A5 (cg-RX-API-DMAC7.html) | ||
| JP2022507506A5 (cg-RX-API-DMAC7.html) | ||
| US20230174508A1 (en) | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| JP6924267B2 (ja) | ピロロ[1,2−b]ピリダジン誘導体 | |
| JP6933770B2 (ja) | Hivカプシド阻害剤のコリン塩形態 | |
| JP7050751B2 (ja) | Nlrp活性に関連する状態を処置するための化合物および組成物 | |
| JP6662863B2 (ja) | P38キナーゼ阻害剤としての4−(4−(4−フェニルウレイドナフタレン−1−イル)オキシピリジン−2−イル)アミノ安息香酸誘導体 | |
| JP2021008516A (ja) | Hivウイルス感染症の予防的または治療的処置に有用な治療用化合物 | |
| JP6464384B2 (ja) | キナーゼ阻害剤 | |
| US8338448B2 (en) | Chemokine receptor modulators | |
| JP2019519598A5 (cg-RX-API-DMAC7.html) | ||
| JP2020537657A5 (cg-RX-API-DMAC7.html) | ||
| JP2019515952A5 (cg-RX-API-DMAC7.html) | ||
| JP2021530536A (ja) | インターロイキン−1活性の阻害剤としてのスルホニル尿素化合物 | |
| AU2021306755B2 (en) | Immunomodulator | |
| JP2019518071A5 (cg-RX-API-DMAC7.html) | ||
| CN112368278A (zh) | Rip1抑制性化合物以及制备和使用其的方法 | |
| TW201102389A (en) | Fused pyrroloprydine derivatives | |
| TWI425945B (zh) | 四氫異喹啉-1-酮衍生物或其鹽 | |
| JP2022507505A5 (cg-RX-API-DMAC7.html) | ||
| JP2018529714A (ja) | Hivの処置のための化合物および組合せ物 | |
| TWI828289B (zh) | 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法 | |
| JP5806420B1 (ja) | カルボキシメチルピペリジン誘導体 |